Empowered Funds LLC Trims Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Empowered Funds LLC reduced its stake in ADMA Biologics by 11.5%, now holding 293,227 shares valued at approximately $5.82 million.
• ADMA Biologics reported a quarterly earnings per share (EPS) of $0.15, surpassing estimates, with a revenue of $121.98 million, a 13.8% increase from the previous year.
• Institutional investors own 75.68% of ADMA Biologics, indicating significant financial backing from hedge funds and other large entities.

Empowered Funds LLC cut its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 11.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 293,227 shares of the biotechnology company's stock after selling 37,982 shares during the period. Empowered Funds LLC owned about 0.12% of ADMA Biologics worth $5,818,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Invesco Ltd. increased its stake in ADMA Biologics by 13.9% in the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock valued at $255,279,000 after purchasing an additional 1,570,649 shares during the period. Nuveen LLC acquired a new position in ADMA Biologics during the first quarter worth about $93,543,000. American Century Companies Inc. grew its position in ADMA Biologics by 12.7% during the first quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company's stock worth $84,367,000 after buying an additional 478,800 shares during the period. Allspring Global Investments Holdings LLC grew its position in ADMA Biologics by 7.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock worth $59,211,000 after buying an additional 207,097 shares during the period. Finally, Driehaus Capital Management LLC grew its position in ADMA Biologics by 114.9% during the first quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company's stock worth $58,460,000 after buying an additional 1,575,363 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

ADMA traded up $0.14 on Wednesday, hitting $15.83. 371,240 shares of the company were exchanged, compared to its average volume of 3,122,424. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The business's fifty day moving average is $17.38 and its 200 day moving average is $18.96. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The firm has a market capitalization of $3.78 billion, a P/E ratio of 18.43 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period in the prior year, the business posted $0.13 earnings per share. The firm's revenue for the quarter was up 13.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.